Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
172.14B
Market cap172.14B
Price-Earnings ratio
9.55
Price-Earnings ratio9.55
Dividend yield
3.14%
Dividend yield3.14%
Average volume
9.37M
Average volume9.37M
High today
$39.03
High today$39.03
Low today
$38.54
Low today$38.54
Open price
$38.57
Open price$38.57
Volume
4.72M
Volume4.72M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

The Motley Fool 4h
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The pharmaceutical industry is evolving rapidly, leaving many investors to wonder whether established giants can sustain their momentum. Choosing between Amgen...

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Benzinga 8h
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible

Eli Lilly (NYSE:LLY) can continue running advertisements for its weight-loss medicines after a federal judge rejected Novo Nordisk A/S‘ (NYSE:NVO) request for a...

Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible
Bloomberg 22h
Novo Nordisk Loses Court Ruling Over Eli Lilly Obesity Drug Ads - Bloomberg.com

...

Novo Nordisk Loses Court Ruling Over Eli Lilly Obesity Drug Ads - Bloomberg.com

Analyst ratings

50%

of 6 ratings
Buy
16.7%
Hold
50%
Sell
33.3%

More NVO News

TipRanks 1d
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Novo Nordisk ( (NVO) ) just unveiled an announcement. On 26 October 2026, Novo Nordisk reported progress in a major share repurchase programme that forms part...

The Motley Fool 5d
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Bristol-Myers Squibb: Delivering Stable Revenue Across Recent Quarters Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex pr...

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
Simply Wall St 6d
Novo Nordisk, Why Is Fresh Attention Building Now?

OpenAI’s acquisition of biotech software startup Orchestra Bio has pulled Novo Nordisk (NYSE:NVO) into the spotlight again, since the drugmaker already uses Ope...

Novo Nordisk, Why Is Fresh Attention Building Now?
The Motley Fool 6d
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?

In a development that happens far less often than they'd like, Novo Nordisk (NVO +2.42%) investors got a hit of positive news on Tuesday. The company, which sho...

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
TipRanks 7d
Novo Nordisk Stock Climbs 2% Today on Positive CagriSema Weight-Loss Data

Novo Nordisk (NVO) stock scored an almost 2% rise on Tuesday after the pharmaceutical firm announced new data from its CagriSema weight-loss drug. The company s...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.